KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Intangibles (2016 - 2021)

Historic Change in Intangibles for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q1 2021 value amounting to $453000.0.

  • Supernus Pharmaceuticals' Change in Intangibles changed N/A to $453000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $594000.0, marking a year-over-year decrease of 5593.47%. This contributed to the annual value of $1.3 million for FY2019, which is 6674.91% up from last year.
  • According to the latest figures from Q1 2021, Supernus Pharmaceuticals' Change in Intangibles is $453000.0.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Intangibles peaked at $5.8 million during Q2 2017, and registered a low of $1000.0 during Q1 2019.
  • Moreover, its 5-year median value for Change in Intangibles was $343000.0 (2018), whereas its average is $1.1 million.
  • Within the past 5 years, the most significant YoY rise in Supernus Pharmaceuticals' Change in Intangibles was 93692.31% (2019), while the steepest drop was 9970.85% (2019).
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Change in Intangibles stood at $1.0 million in 2017, then plummeted by 87.3% to $130000.0 in 2018, then skyrocketed by 936.92% to $1.3 million in 2019, then plummeted by 91.32% to $117000.0 in 2020, then surged by 287.18% to $453000.0 in 2021.
  • Its last three reported values are $453000.0 in Q1 2021, $117000.0 for Q3 2020, and $24000.0 during Q2 2020.